Brain Hemorrhage Market Analysis & Forecast: 2026-2033
The Brain Hemorrhage Market size is anticipated to grow at a CAGR of 6.0% with USD 240.6 Mn in 2026 and is expected to reach USD 361.8 Mn by 2033. The market growth is primarily driven by the increasing prevalence of intracerebral and subarachnoid hemorrhage, rising incidence of hypertension and traumatic brain injuries, growing geriatric population, and increasing demand for advanced diagnostic and treatment modalities. According to the World Stroke Organization (WSO) Global Intracerebral Hemorrhage Factsheet 2025, more than 3.4 Mn new cases of intracerebral hemorrhage occur worldwide each year, and intracerebral hemorrhage accounts for 28.8% of all incident strokes worldwide.
Increasing prevalence of traumatic brain injuries (TBI) and road traffic accidents is highly supporting the growth of the brain hemorrhage market. Intracerebral, subdural, and epidural hemorrhages are common sequelae of severe head trauma, and require rapid identification and intervention. The need for neurocritical care and emergency interventions is further augmented by expanding urbanization, increased vehicular density, sports injuries and falls in elderly.
According to the World Health Organization (WHO) estimates that road traffic injuries kill over 1.19 million people each year, while tens of millions more people receive non-fatal injuries, many of which include traumatic brain injury and associated cerebral bleeding.
The market is expanding due to rising healthcare expenditure in specialized stroke facilities, which are enhancing accessibility to sophisticated diagnostics, neurocritical care units, and surgical procedures. Governments and healthcare facilities are developing their stroke network and emergency service systems in an effort to minimize mortality rates and enhance results; this will increase demand for brain hemorrhage treatments and technologies.
In addition, in 2025, the Radiological Society of North America (RSNA) disclosed that the use of AI greatly reduces time-to-diagnosis in cases of stroke and cerebral hemorrhage, increasing emergency treatment efficiency.
In February 2025, the European Stroke Organisation (ESO) revised its recommendations for stroke centers, stressing the need for comprehensive stroke centers with neuroimaging and neurosurgical capabilities to optimize outcomes for patients with hemorrhagic stroke.
|
Current Event |
Description and its Impact |
|
Updated AHA/ASA Guidelines Promote Minimally Invasive Treatment for Intracerebral Hemorrhage |
|
|
FDA Expansion of AI-Enabled Medical Devices Enhances Brain Hemorrhage Diagnosis |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
By Drug Type, the Brain Hemorrhage market is segmented into Anti-hypertensive medications, Thrombolytic drugs, Coagulants, and Others. The Anti-hypertensive drugs segment is expected to hold the biggest share of 41.8% by 2026. The expansion of the segment is explained by the widespread use of blood pressure lowering medications both in the setting of acute and secondary prophylaxis, as hypertension is the most major modifiable risk factor for intracerebral hemorrhage.
Furthermore, the American Heart Association’s 2025 heart disease and Stroke Statistics Update indicated that almost 47% of U.S. adults have hypertension, indicating the large patient population requiring antihypertensive medication.
In April 2026, NeurologyLive published data from the Phase III TRIDENT study showing that GMRx2, a fixed-dose triple antihypertensive tablet including telmisartan, amlodipine, and indapamide, reduced the incidence of recurrent stroke by 39% in patients with a history of intracerebral hemorrhage.
To learn more about this report, Request Free Sample
On the basis of distribution channel, the hospital pharmacies category is expected to lead with a healthy 67.3% share in 2026. The increase is due to the fact that brain hemorrhage is a life-threatening neurological emergency that requires rapid hospitalization, rigorous monitoring and drug delivery under specialized supervision. Medication delivery mainly happens in hospital settings due to the necessity for quick blood pressure management, reversal of anticoagulation, seizure prevention, and neurocritical care.
According to the American Hospital Association (AHA), U.S. hospitals reported around 33.7 million admissions in 2024, which indicates a huge patient base managed through hospital pharmacies.
In April 2026, Grace Therapeutics reported that the U.S. FDA issued a Complete Response Letter for GTx-104, an IV formulation of nimodipine being developed for aneurysmal subarachnoid hemorrhage (aSAH).
To learn more about this report, Request Free Sample
North America Brain Hemorrhage Market share accounted for 39.4 % in 2026. The expansion of the region is due to availability of modern neurocritical care units, wide availability of CT and MRI imaging, favourable reimbursement systems, and rising use of minimally invasive neurosurgery operations. Presence of specialized stroke centers and top pharmaceutical and medical devices businesses aids the market expansion.
According to the American Hospital Association (AHA) Fast Facts on U.S. Hospitals, 2026, there are 6,100 hospitals in the U.S., including 5,121 community hospitals, with an estimated 35.7 million total hospital admissions each year and more than 907,000 staffed beds. This demonstrates the significant healthcare infrastructure that is available for acute neurological emergencies and the capacity to provide prompt diagnosis and treatment for patients with brain hemorrhage.
In February 2025, Stryker Corporation announced the growth of its neurovascular portfolio and stroke care solutions through intensified commercialization activities across North America, in response to the growing demand for innovative hemorrhagic stroke management technology.
Asia Pacific is expected to witness the fastest growth in the Brain Hemorrhage Market during the forecast period. The growth in the region is attributed to the increasing incidence of hypertension, rapid aging population, growing healthcare spending, and rising access to stroke treatment facilities across China, Japan, India, and South Korea. Governments are investing more and more in the care of neurological diseases and the development of emergency stroke networks, which is propelling market growth.
Based on the World Stroke Organization Worldwide Stroke Fact Sheet 2025, an estimated 86% of deaths resulting from stroke occur in low- and middle-income countries. Asia represents a substantial proportion of the global burden of stroke.
In March 2026, MicroPort NeuroTech announced that its neurovascular range had been expanded to 27 NMPA-approved products, while six other products were recognized as Innovative Medical Devices under the “Green Path” program in China.
The U.S. Brain Hemorrhage Market growth is driven by the presence of advanced stroke management systems, growing adoption of imaging modalities based on artificial intelligence, and rising expenditure on health care. The U.S. has an extensive network of stroke centers and neurological critical care centers, which help detect intracranial hemorrhages at an early stage.
According to CDC’s NCHS, stroke was the fourth leading cause of deaths in the U.S. in 2024 with a mortality rate of 166,852 deaths, indicating the immense burden on neurological health care system as well as the demand for advanced hemorrhagic stroke treatment.
In April 2025, Bioxodes announced positive Phase IIa interim data for its first-in-class candidate BIOX-101 in patients with intracerebral hemorrhagic stroke.
Japan’s Brain Hemorrhage Market is rising because to the fast-aging population, high prevalence of hypertension, and ongoing investments in stroke detection and treatment infrastructure in the country. The market expansion is further supported by increasing adoption of less invasive neurovascular operations and advanced imaging technology.
According to the Statistics Bureau of Japan reported in 2025 that 29.3% of Japan’s population was aged 65 or older, which makes Japan one of the oldest societies in the world and increases the risk of hemorrhagic stroke.
In July 2025, Terumo Corporation announced progress in strengthening its neurovascular solutions business in Japan and globally through its Terumo Neuro division.
Some of the major key players in Brain Hemorrhage Market are Baxter, Oxurion NV, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, Novartis AG, Bayer AG, Abbott, Bristol-Myers Squibb, Johnson and Johnson, Neurotech Pharmaceuticals, Inc., Siemens Healthcare GmbH, Novo Nordisk A/S, H. Lundbeck A/S, and Ligand Pharmaceuticals Incorporated.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 240.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.0% | 2033 Value Projection: | USD 361.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Baxter, Oxurion NV, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, Novartis AG, Bayer AG, Abbott, Bristol-Myers Squibb, Johnson and Johnson, Neurotech Pharmaceuticals, Inc., Siemens Healthcare GmbH, Novo Nordisk A/S, H. Lundbeck A/S, and Ligand Pharmaceuticals Incorporated |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
